fbpx

YOUR GUIDE TO STAYING INFORMED IN THE MARKETS

Subscribe for FREE Email Updates & Access To EXCLUSIVE Research!

INVO

INVO Bioscience

  ( )

Page Views : 219294

Analyst Ratings

 
Strong
Buy
Strong Buy
50%
Buy
50%
Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.
Sector
:
Healthcare
Industry
:
Medical Devices
Exchange
:
Nasdaq
Ticker
:
INVO

vista's key points

  • INVO operates within the ~$15-$18 Billion global infertility industry growing ~8-10% annually.
  • INVO is commercializing the world's only in vivo Intravaginal Culture System (IVC), INVOcell®, an accessible, inclusive, and affordable treatment for patients diagnosed with infertility.
  • INVOcell is an FDA cleared patented medical device that is one of only 3 ways today that a couple that is struggling with infertility may choose to use to try to get pregnant and that offers a more economical and natural way to proceed.
  • INVOcell addresses key industry challenges regarding cost & capacity constraints of in vitro- fertilization (IVF).
  • INVOcell is positioned to serve a vastly underserved global market as ~+90% of infertile individuals go untreated exposing a significant unmet market opportunity.
  • INVO is pushing forward with a combined distribution, joint venture/partner model to establish INVO-only clinics (2 open in the US & 1 in Mexico) to accelerate adoption of INVOcell and their business worldwide.
  • INVO now has distribution agreements in place in within 9 countries in Africa, Asia (China, Taiwan), Europe, & Middle East continues to seek further relationships worldwide.
  • INVO opened INVOcell dedicated clinics or INVO Centers in Atlanta & Birmingham in 2021 & is seeking to open 1 the San Francisco Bay Area
  • INVO opened first INVO Center in Mexico Q4/2021.
  • INVO a "low" or "tight float" with only 12.7M shares issued and outstanding as of Jan 1, 2023.

Click Here To Learn More

vista's key points

  • INVO operates within the ~$15-$18 Billion global infertility industry growing ~8-10% annually.
  • INVO is commercializing the world's only in vivo Intravaginal Culture System (IVC), INVOcell®, an accessible, inclusive, and affordable treatment for patients diagnosed with infertility.
  • INVOcell is an FDA cleared patented medical device that is one of only 3 ways today that a couple that is struggling with infertility may choose to use to try to get pregnant and that offers a more economical and natural way to proceed.
  • INVOcell addresses key industry challenges regarding cost & capacity constraints of in vitro- fertilization (IVF).
  • INVOcell is positioned to serve a vastly underserved global market as ~+90% of infertile individuals go untreated exposing a significant unmet market opportunity.
  • INVO is pushing forward with a combined distribution, joint venture/partner model to establish INVO-only clinics (2 open in the US & 1 in Mexico) to accelerate adoption of INVOcell and their business worldwide.
  • INVO now has distribution agreements in place in within 9 countries in Africa, Asia (China, Taiwan), Europe, & Middle East continues to seek further relationships worldwide.
  • INVO opened INVOcell dedicated clinics or INVO Centers in Atlanta & Birmingham in 2021 & is seeking to open 1 the San Francisco Bay Area
  • INVO opened first INVO Center in Mexico Q4/2021.
  • INVO a "low" or "tight float" with only 12.7M shares issued and outstanding as of Jan 1, 2023.

Click Here To Learn More
Sector
:
Healthcare
Industry
:
Medical Devices
Exchange
:
Nasdaq
Ticker
:
INVO

company profile

 

INVO Bioscience, Inc. (NASDAQ: INVO) is a commercial-stage fertility company dedicated to expanding the assisted reproductive technology (“ART”) marketplace by making fertility care accessible and inclusive to people around the world. Their flagship product is INVOcell®, a revolutionary medical device that allows fertilization and early embryo development to take place in vivo within the woman’s body. Their primary mission is to implement new medical technologies aimed at increasing the availability of affordable, high-quality, patient-centered fertility care. This treatment solution is the world’s first intravaginal culture technique for the incubation of oocytes and sperm during fertilization and early embryo development. This technique, designated as “IVC”, provides patients a more natural, intimate, and more affordable experience in comparison to other ART treatments. The IVC procedure can deliver comparable results at a fraction of the cost of traditional in vitro fertilization (“IVF”) and is a significantly more effective treatment than intrauterine insemination (“IUI”). Our commercialization strategy is focused on the opening of dedicated “INVO Centers” offering the INVOcell® and IVC procedure (with three centers in North America now operational), in addition to continuing to sell our technology solution into existing fertility clinics. For more information, please visit www.invobio.com.

vista's view

INVO Bioscience (INVO) is an emerging growth company that owns the INVOcell system, an FDA cleared patented medical device that is one of only 3 ways today that a couple that is struggling with infertility may choose to use to try to get pregnant and that offers a more economical...

Read More

exclusive content

 

Vista Partners creates exclusive content based on the ongoing research of companies included in the VP Watchlist.

vp watchlist

The VP Watchlist contains current coverage companies that deserve consideration for short term and long term portfolio additions.